clinical trialsworldpharmanews2018-02-11 17:22Read 4
A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first time, researchers have regenerated patients' damaged lungs using autologous lung stem cell transplantation in a pilot clinical trial. The study can be found in the open access journal Protein & Cell which is published by Springer Nature.
Commentspmlive2018-02-11 17:18Read 4
Boehringer Ingelheim’s Ofev subject to same conditions
TrendBiospace2018-02-11 09:23Read 3
The first of the pink slips at Sandoz’ generic-drug manufacturing facility in Broomfield, Colo. have been handed out. The company issued 65 layoff notices this week, BizWest reported, citing a WARN notice filed with the Colorado Department of Labor and Employment.
Trendpmlive2018-02-11 09:20Read 2
GlaxoSmithKline could reach the end of 2018 without generic competition to its big-selling Advair respiratory drug in the US, after the FDA rejected Novartis’ rival.
TrendEPVantage2018-02-11 09:20Read 1
Sarepta made a neat transition from its marketed Duchenne muscular dystrophy drug, Exondys 51, to developing what could be an even better asset, golodirsen. But there could be trouble ahead: treatment at UK sites involved in the latter’s pivotal trial has just been halted, EP Vantage has learned.
clinical trialsEORTC2018-02-11 09:16Read 2
Avoidance of side-effects of chemotherapy is particularly important in the elderly, but finding the balance between reduced toxicity and maximum effectiveness is not always easy.
clinical trialsAstraZeneca2018-02-11 09:16Read 5
AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.
clinical trialsDrugs2018-02-11 08:55Read 1
Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows.
Trendxconomy2018-02-09 09:13Read 2
Teva Pharmaceutical’s bid to bring a new migraine drug to the market faces a possible delay due to manufacturing problems found with one of the company’s partners, and observers are skeptical about whether Teva will be able to get it over the finish line.
Trendworldpharmanews2018-02-09 09:11Read 3
Roche and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc
TrendASCO GU 20182018-02-09 09:08Read 2
The study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.
TrendPBR2018-02-09 09:08Read 2
Janssen Biotech will co-develop Theravance’s TD-1473 and associated backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease, through an agreement that is potentially worth about $1bn.